Determination of the pharmacokinetics of rituximab and antibodies to rituximab in patients with a B-cell CD20+ malignancy who are treated with rituximab as single agent or rituximab in combination with chemotherapy or are on maintenance therapy with rituximab
- Conditions
- 10025320B-cell non-Hodgkin lymphoma
- Registration Number
- NL-OMON31559
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
· All patients with a CD20+ B-cell malignancy who are treated with rituximab are eligible for this study.
· Written informed consent
Exclusion Criteria
no written informed consent
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method